

Special Issue

Cystectomy for Bladder Cancer

Message from the Guest Editor

We would love for you contribute to a Special Issue of *Cancers*, entitled “Cystectomy for bladder cancer”. During recent years, there has been a refinement regarding several aspects in preoperative, intraoperative, and postoperative pathways and management. This Special Issue of *Cancers* aims to present a selection of original articles and reviews which describe the recent advances and current challenges in the field. Specifically, we aim to provide a comprehensive understanding of all aspects of cystectomy to point out modern approaches that are state-of-the-art. Research areas may include (but are not limited to) surgical techniques, the impact of enhanced recovery protocols, perioperative systemic therapy, pathological and genetic prognostic markers, as well as volume outcome relationships. Metabolic, immunological, and other specific features of muscle-invasive bladder cancer are also of interest. Thus, we are pleased to invite manuscripts that aid the translation of data into routine clinical practice for more specific and individual therapeutic options for this disease. We look forward to receiving your contributions.

Guest Editor

Dr. Tobias Klatte

Department of Urology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany

Deadline for manuscript submissions

closed (31 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/115098

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)